Factor XllIa is a transglutaminase (EC 2.3.2.13) that forms y-glutamyl-e-lysyl intermolecular bonds within peptides and proteins. It is the final enzyme in the blood-clotting cascade and acts to consolidate nascent clots by forming cross-links between fibrin, linking a-2-antiplasmin to the fibrin network and linking fibrin to cell surface proteins such as fibronectin and thrombospondin [ 11. It is found in plasma as a tetrameric proenzyme (a2b2) and in platelets as a dimeric proenzyme (a2). Both species are activated by limited proteolysis in the presence of calcium to give ultimately the active enzyme (a2*) 121.
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It has been hypothesized [3-Y] that inhibition of factor Xllla-mediated processes should lead to a blood clot that is physically and biochemically less stable to lysis. As a preliminary study that might lead to a clinically useful inhibitor of factor XIIIa, the substrate requirements of the enzyme have been investigated. We have examined both the size of peptide and the effect of each of the residues on the binding of a substrate to factor Xllla. The enzyme active-site thiol forms a thio-acyl intermediate as the rate-limiting step in catalysis. Identification of a suitable substrate allowed us to substitute the reactive glutamine residue with a variety of electrophilic glutamine analogues to mimic the transition state or react with the active-site thiol.
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IXscirssion
Thrombolysis is becoming a commonplace treatment for acute thrombotic episodes via the use of a variety of plasminogen activators (e.g. tissue plasminogen activator). However, these therapies are not suitable for long-term management of thrombo-embolic disease. This aim might be achieved by the facilitation of endogenous fibrinolysis by the inhibition of factor Xllla. Our initial strategy was to design substrate-based inhibitors; thus, it was necessary to ascertain the substrate requirements of the enzyme.
Recent work has demonstrated that the N-terminal dodecapeptide of a-2-antiplasmin (Asn-Gln-Glu-Gln-Val-Ser-ProLeu-Thr-Gly-Leu-Lys) is a good [glutamine] substrate for factor Xllla [ 101. It was also inferred that of the two glutamine residues, only Gln-2 acts as an amine acceptor. Using this peptide as the basis of our studies, we have looked at smaller fragments and the role of the individual residues. The results are summarized in Table, it is apparent that not only can the size of peptide be reduced dramatically (to that of a pentapeptide), but a protected tripeptide appears to bind more tightly. It is worth noting that the dodecapeptide itself only binds at millimolar concentrations. Physiologically, this may not be important since factor Xlll is able to form a complex with polymeric fibrin before activation [ 121; therefore, the local concentration of substrate is high and presumably the active enzyme does not need to bind substrates tightly.
The sequential replacement of residues with alanine reveals that functional groups either side of the reactive glutamhe are important for binding. The replacement of the second glutamine (Gln-4) with alanine shows that this glutamine residue is not involved in any strong interactions with the enzyme. The more conservative replacement o f valine (Val-5) with alanine could not be tested due t o solubility problems.
Labelled putrescine was incorporated via factor XIlla into the pentapeptide Asn-Gln-Glu-Gln-Val and the resulting peptide degraded by reaction with Staph?'loc.oc,cir.s aiireiis V8 protease (post-Glu cleaving) to produce two fragments. A combination of h.p.1.c. and amino acid analysis demonstrated that putrescinc had been incorporated exclusively into Gln-2.
Although the binding of these substrate peptides (Table 1 ) appears very similar, the efficiency with which the enzyme is able to transaminate them, as measured by k,;,,,, is very different: the data are summarized in Table 2 . We conclude that, whereas the pentapeptides bind in a similar way t o the dodecapeptide and are recognized as substrates, the tripeptides either bind at the active site in a non-productive mode, or at another site in such a way as t o block the access of true substrates to the active site.
Thus, from these data, the pentapeptide Asn-Gln-GluAla-Val, with kinetic constants close to that o f the dodecapeptide, was chosen as a suitable substrate on which to base (Fig. 1 ) .
The thiol protease protein papain is strongly inhibited by suitable nitriles; a reversible, covalent adduct is believed to be formed, probably a thioimidate [lY]. The synthesis of a suitable glutamine analogue was straightforward: dicyclohexylcarbodi-imide dehydration of either benzyloxycarbonyl-o r fluorenyloxycarbonyl-glutamine gave a fragment suitable for peptide synthesis [20].
The strategy for aldehyde synthesis was based on the incorporation of a protected bis-homoserine and subsequent oxidation. The fragment, derived from glutamic acid via reduction of a y-carboxyanhydride, was introduced into peptides by conventional methodology. Deprotection of the pendant alcohol, followed by oxidation with the Dess-Martin reagent [ 2 11 (periodinane) gave the corresponding aldehyde, which exists as a cyclic aminal ( 5 -hydroxyproline).
The synthesis of the trifluoromethylketone began with commercially available ethyl 3-hydroxy-4,4,4-trifluorobutyrate. Protection as the TBDMS ether was followed by low temperature reduction and two-step conversion to the bromide. Alkylation of a suitable imine by the Stork procedure with this synthon and subsequent hydrolysis gave a diastereomeric mixture of an amino acid benzyl ester which was used to construct the appropriate peptide. Deprotection of the peptidic silyl ether proceeded smoothly and oxidation was achieved, again by the use of the Dess-Martin reagent [22] . The individual diastereoisomers (epimeric at the trifluoromethylketone amino acid methine) were separable when incorporated in a tripeptide, but not separable in the pentapeptide. Another product of the oxidation was identified as a peptide containing aminopropionic acid, derived from Hofmann rearrangement of the asparagine residue.
Certain diazoketones have been shown to be irreversible inactivators of thiol proteases. For our purposes, this tactic would require the diazoketone derived from glutamic acid. The usual method of synthesis (the action of diazomethane o n an activated carboxylic acid) could be applied to a protected amino acid, but was considered too problematic in terms of stability to be applied to conventional peptide synthesis. Direct activation of a glutamic acid within a peptide to produce a diazoketone could only be achieved in model systems; more often, facile cyclization t o the five-o r sixmembered lactam intervened. The approach was abandoned, therefore, in favour of one based on a more stable thiol trap, the 3-halodihydroisoxazole.
During the course of this work, data were published concerning the elegant use of 3-halodihydroisoxazoles as irreversible inhibitors of other transglutaminases [ 17, 181. We were convinced of the value of using enzyme substrates as the template, for reasons of selectivity, and chose to incorporate this moiety as a thiol trap. Vinylglycine was prepared from methionine by the thermal elimination of a protected methionine sulphoxide [23] . Reaction with bromonitrile oxide (generated in situ from dibromoformaldoxime), followed by exchange of protecting groups and diastereoisomer separation by h.p.1.c. gave the required protected amino acids which were introduced into peptides via solution synthesis.
Results
In no case did any of our reversible inhibitors derived from glutamine-containing substrates exhibit any improved binding over the parent sequences. In contrast, reported inhibitors of factor XllIa apparently have irreversible kinetics or else only compete with the second amine substrate. One possible interpretation of our results is that the catalytic steps do not require a tightly-bound transition state. The substrates themselves are not tightly bound, and this enzyme could achieve physiologically competent catalysis merely by concentrating the reactants. In this case, of course, transition state mimics would not be expected to bind tightly. Previous work on the simple dihydroisoxazoles show that these are irreversible inhibitors of an epidermal transglutaminase. However, no inhibition of factor XIlla has been observed with this residue in our peptidic substrates. It is likely that with the constraint of the peptide substrate partial backbone, the dihydroisoxazole is not able to gain access to the thiol; thus it cannot act as a glutamine mimic.
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In summary, a dodecapeptide substrate of factor XllIa has been modified to give a pentapeptide with similar kinetic characteristics. The synthesis of a number of penta-and tripeptide sequences containing electrophilic analogues of glutamine has been successfully achieved and these analogues have been shown to be amenable t o manipulation in peptide synthesis. (The detailed chemistry of these syntheses will be reported elsewhere.) No increase in binding to factor XIlla has been noted with these analogues.
I .
Introdiiction
In recent years a considerable volume of information has emerged on the peptide hormone atrial natriuretic factor, which elicits multiple physiological responses largely directed to the reduction of blood pressure and blood volume. A family of peptides [atrial natriuretic peptides (ANPs)] of varying lengths has been isolated from mammalian atria and shown to have potent diuretic and smooth muscle relaxant activities. The early history of these peptides and their pharmacology has been described in a number of reviews [l-71 and a recent publication [8] gives a comprehensive account of their structure-function relationships. Our own structure-conformation-activity studies were developed with the explicit aim of maximizing agonist potency in ANP analogues of minimum molecular size.
Throughout this article the numbering system [9] for atrial natriuretic peptides will be based upon the 126-residue prohormone, ANP( 1 -126) (proANP). The data reported were obtained in aortic strips isolated from male CD rats and male New Zealand White rabbits under pentobarbitone anaesthesia. Helical strips of aorta, bathed in Krebs solution at 37"C, under a resting tension of 1 g (rat) or 2 g (rabbit) were pre-contracted with noradrenaline ( 1 pmol/l).
The ANP analogues were added cumulatively to the baths to produce concentration ranges encompassing a 50% relaxant effect. If relaxation was incomplete, rANP (1 pmol/l) Abbreviations used: ANP, atrial natriuretic peptide; rANP, ratANP.
*To whom correspondence should be addressed.
was used to establish the maximum value. Median IC,,, (concentration required to inhibit by 50%) values are shown in the Tables. The existence of ANP receptor subtypes 18, 101 has added another dimension t o structure-function relationships which was not available during our studies. The data reported are based purely on the functional assays described above. The preliminary investigations focused on Ala substitutions as a means of evaluating the contribution of each amino acid side chain to receptor recognition. As a matter of expediency linear fragments of the 28-amino acid circulating peptide were investigated:
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I?(, The linear sequences Ac-rANP( 106-120)-NHCH, (IC,,, 470 nM in rabbit aorta) and Ac-[Leu-12 l]rANP( 106-125)-NHCH, (lC,,l 36 nM) were found to retain smooth muscle relaxant activity. The Leu-12 I analogue was 14-fold more potent than the related Cys-12 1-containing fragment which had an 1Cs0 of 490 nM. Substitution of each amino acid in Ac-rANP( 106-120)-NHCH, by Ala indicated that the region Phe-106-Ile-1 13 contained residues important for maintenance of activity. Subsequent synthesis of AcrANP( 106-1 13)-NHCH, [ Table 2 ; (S)] and shorter deletion sequences confirmed that this was the minimum active fragment, a conclusion that has also been reached by other workers in the field [ 10, 1 11.
As activity was reduced in the linear analogues compared with rANP( 99-126), we speculated that the conformational constraint introduced by a ring system would increase potency. Cyclic analogues of rANP( 106-120) (Table I ) were synthesized using Fmoc methodology [ 121 to assemble the protected sequence attached to polydimethylacrylamide via a p-hydroxymethylphenylacetic acid linker. Cleavage from the solid support with hydrazine hydrate and then cyclization
